We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy. 42% of the patients had been systemically pre-treated.
SGN-75, undergoing a phase I trial for metastatic renal cell carcinoma...
igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).
Reliable data on familial risks are important for clinical counseling and cancer genetics.
New cancer drugs are technically impressive. But must they cost so much?
Information about renal cell carcinoma may be found in these abstracts that were presented recently at the world's largest oncology meeting, held in Chicago. The Kidney Cancer Association sponsored the presentation of this information.
We conducted a direct drug-to-drug comparison of the two regulatory agencies approvals of new oncology drugs.
Spring 2011 edition is online.
tthe first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).